drugset / Trial / NCT07635485
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
Not yet recruiting
50 enrolled
The First Affiliated Hospital of Soochow University
Nanfang Hospital, Southern Medical University · collabRuijin Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine（VA) induction followed by bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hypoplastic and secondary acute myeloid leukemia (AML).
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-05-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |